K90-114TAT

K90-114TAT is a rationally designed interfering peptide developed for the treatment of glioblastoma (GBM). It functions by disrupting the interaction between the voltage-gated potassium channel EAG2 (KCNH1) and its regulatory subunit Kvβ2 (KCNAB2). In GBM, the overexpression of Kvβ2 isoform 4 facilitates a tumor-specific interaction with EAG2, which is critical for regulating neuron-GBM communications and calcium transients that drive tumor progression and resistance to temozolomide (TMZ). By blocking this interaction, K90-114TAT reduces tumor cell proliferation, induces apoptosis, and overcomes TMZ resistance. Preclinical studies in patient-derived xenograft mouse models have demonstrated significant tumor burden reduction and prolonged survival with minimal toxicity to normal tissues.